Data presented at the ECCO (European Crohn's and Colitis Organisation) support the potential of Abivax's ABX464 in ulcerative colitis ("UC") While response to biologic therapies such as anti-TNF often wains with time and alternatives including JAK inhibitors are associated with serious safety issues, six month Phase 2a extension data indicate safety and progressive improvements from ABX464 in key UC disease markers, including Mayo Score and faecal calprotectin over the eight months since the ori ....
11 Mar 2019
ABX464: sustained safety and benefit in inflammatory bowel
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ABX464: sustained safety and benefit in inflammatory bowel
Abivax SA (0RA9:LON) | 0 0 0.5% | Mkt Cap: 83.0m
- Published:
11 Mar 2019 -
Author:
Chris Redhead -
Pages:
5
Data presented at the ECCO (European Crohn's and Colitis Organisation) support the potential of Abivax's ABX464 in ulcerative colitis ("UC") While response to biologic therapies such as anti-TNF often wains with time and alternatives including JAK inhibitors are associated with serious safety issues, six month Phase 2a extension data indicate safety and progressive improvements from ABX464 in key UC disease markers, including Mayo Score and faecal calprotectin over the eight months since the ori ....